<SUBMISSION>
<SECRELEASE-DATETIME>		20240426-164133	 ⇐ Metadata from SEC Info (ET)
<SECWEBSITE-DATETIME>		20240426-164131	 ⇐ Metadata from SEC Info (ET)
<ACCEPTANCE-DATETIME>		20240426-163957	 ⇐ Filing accepted by SEC (ET)
<ACCESSION-NUMBER>		0001193125-24-118225
<TYPE>				ARS
<PUBLIC-DOCUMENT-COUNT>		1
<PERIOD>			20231231
<FILING-DATE>			20240426
<DATE-OF-FILING-DATE-CHANGE>	20240426
<EFFECTIVENESS-DATE>		20240426

<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>		Akero Therapeutics, Inc.
<CIK>				0001744659
<ASSIGNED-SIC>			2834
<ORGANIZATION-NAME>		03 Life Sciences
<IRS-NUMBER>			000000000
<STATE-OF-INCORPORATION>	DE
<FISCAL-YEAR-END>		1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>			ARS
<ACT>				34
<FILE-NUMBER>			001-38944
<FILM-NUMBER>			24884585
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>			601 GATEWAY BOULEVARD, SUITE 350
<CITY>				SOUTH SAN FRANCISCO
<STATE>				CA
<ZIP>				94080
<PHONE>				650-487-6488
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>			601 GATEWAY BOULEVARD, SUITE 350
<CITY>				SOUTH SAN FRANCISCO
<STATE>				CA
<ZIP>				94080
</MAIL-ADDRESS>
</FILER>

<DOCUMENT>
<TYPE>		ARS
<SEQUENCE>	1
<FILENAME>	d830043dars.pdf
<DESCRIPTION>	ARS
<TEXT>
<PDF>
       Show <PDF>: 225,250 lines (Unix-to-Unix encoding) - 13.3M bytes  
</TEXT>
</DOCUMENT>

</SUBMISSION>